CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – July 15, 2026 – Nava is planning its first clinical trial in autoimmune disease in the first half of 2027. Nava’s second program could break new ground. The company has also designed lipid nanoparticles that target the kidney, an organ that’s long been out of reach for genetic medicines. Successful delivery could open doors to treating many rare and common diseases with no or few good options.
About Nava Therapeutics
Nava Therapeutics is a biotechnology company developing a new generation of genetic medicines through precision RNA delivery. By combining rational lipid design with high-throughput discovery, Nava has built a proprietary LNP platform capable of selectively targeting cells and tissues beyond the liver.
Business Development contact
For partnership, licensing, or collaboration inquiries, please reach out to bd@navatx.com.
General Inquiries contact
For all other inquiries, please reach out to info@navatx.com.